share_log

Earnings Troubles May Signal Larger Issues for SonoScape Medical (SZSE:300633) Shareholders

Earnings Troubles May Signal Larger Issues for SonoScape Medical (SZSE:300633) Shareholders

收益問題可能預示着SonoScape Medical (SZSE:300633)股東面臨更大的問題。
Simply Wall St ·  09/07 20:14

A lackluster earnings announcement from SonoScape Medical Corp. (SZSE:300633) last week didn't sink the stock price. We think that investors are worried about some weaknesses underlying the earnings.

上週,SonoScape醫療公司(SZSE:300633)發佈的業績公告平淡無奇,但股價並未下跌。我們認爲投資者擔心業績底下存在一些弱點。

big
SZSE:300633 Earnings and Revenue History September 8th 2024
SZSE:300633的盈利和營業收入歷史數據(2024年9月8日)

The Impact Of Unusual Items On Profit

除了稀釋之外,還應該注意的是,萬集科技在過去12個月中因不尋常項目獲得了價值人民幣3.5萬元的利潤。雖然我們希望看到利潤增加,但當這些不尋常項目對利潤做出重大貢獻時,我們會更加謹慎。我們對全球大部分上市公司的數據進行了分析,發現不尋常項目往往是一次性的。這正如我們所期望的那樣,因爲這些提升被描述爲"不尋常"。相對於其利潤而言,萬集科技在2021年12月前的不尋常項目貢獻大。因此,我們可以推斷出,這些不尋常項目正在使其財務利潤顯著增強。

Importantly, our data indicates that SonoScape Medical's profit received a boost of CN¥33m in unusual items, over the last year. While it's always nice to have higher profit, a large contribution from unusual items sometimes dampens our enthusiasm. When we crunched the numbers on thousands of publicly listed companies, we found that a boost from unusual items in a given year is often not repeated the next year. Which is hardly surprising, given the name. If SonoScape Medical doesn't see that contribution repeat, then all else being equal we'd expect its profit to drop over the current year.

重要的是,我們的數據顯示,過去一年,SonoScape醫療公司的利潤在飛凡項目上增加了3300萬人民幣。雖然高利潤總是令人欣喜的,但飛凡項目的大額貢獻有時會減低我們的熱情。當我們對成千上萬家上市公司的數字進行分析時,我們發現,飛凡項目在某一年的增長通常不會在下一年重複出現。這並不奇怪,考慮到其名稱。如果SonoScape醫療公司沒有看到這種貢獻的重複,那麼在其他條件不變的情況下,我們預計其今年的利潤將會下降。

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

這可能會讓您想知道分析師對未來盈利能力的預測。幸運的是,您可以單擊此處查看基於其估計的未來盈利能力的互動圖表。

Our Take On SonoScape Medical's Profit Performance

我們對SonoScape醫療公司的利潤表現的看法

We'd posit that SonoScape Medical's statutory earnings aren't a clean read on ongoing productivity, due to the large unusual item. Because of this, we think that it may be that SonoScape Medical's statutory profits are better than its underlying earnings power. But on the bright side, its earnings per share have grown at an extremely impressive rate over the last three years. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. So while earnings quality is important, it's equally important to consider the risks facing SonoScape Medical at this point in time. At Simply Wall St, we found 1 warning sign for SonoScape Medical and we think they deserve your attention.

我們認爲SonoScape Medical的法定收入並不是對 ongoing productivity 的乾淨解讀,因爲有一個較大的飛凡項目。因此,我們認爲SonoScape Medical的法定利潤可能比其潛在收益能力更好。但好消息是,其每股收益在過去三年中增長速度非常令人印象深刻。當然,在分析其收益方面,我們只是淺嘗輒止;還可以考慮利潤率、預測增長率和投資回報率等其他因素。因此,儘管收益質量很重要,但同樣重要的是考慮SonoScape Medical目前面臨的風險。在Simply Wall St,我們發現了SonoScape Medical的一個警示標誌,並且認爲值得關注。

This note has only looked at a single factor that sheds light on the nature of SonoScape Medical's profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.

這篇文章只看了SonoScape Medical利潤性質的一個方面,但還有很多其他方法可以了解公司。有些人認爲高股本回報率是質量優秀的企業的一個好標誌。所以您也可以查看這個擁有高股本回報率的公司的免費集合,或者這個擁有高內部持股的股票列表。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論